Rani Therapeutics

Rani Therapeutics aims to eliminate painful injections for millions of patients worldwide.

The page presents Rani Therapeutics' story, mission, and leadership team.

The page provides contact information for Rani Therapeutics' Fremont and San Jose offices.

Millions of patients with chronic conditions require biologic drugs that can currently only be injected. Rani Therapeutics believes the RaniPill capsule is a solution for oral delivery of biologics.

The page explains how Rani Therapeutics collects, uses, and shares personal information.

Rani Therapeutics reports a Q2 2026 net loss of **$8.4 million** and holds **$53.4 million** in cash and securities. The company advances **RT-114**, a drug candidate in a Phase 1a trial, after early results showed **oral bioavailability exceeding 150%** compared to subcutaneous dosing. Phase 1b testing for obesity indications is planned, with full expansion data anticipated by year-end.

Aug 2026RTTNewsNews article

Rani Therapeutics advances its Phase 1 study of **RT-114**, delivered via its proprietary **RaniPill®** platform, targeting obesity in partnership with **ProGen**. The company releases first-quarter 2026 financial results alongside a corporate update and announces a transition in its CFO role. The study progresses under the collaboration framework with ProGen, though no new milestones or efficacy data are disclosed.

May 2026BioSpaceNews article

Rani Therapeutics reports an $8.0 million net loss and $1.7 million in revenue for Q1 2026, with $43.4 million in cash reserves. The company advances its obesity drug candidate, **RT-114**, into clinical trials while announcing a leadership change, replacing its chief financial officer.

May 2026Stock TitanNews article

Rani Therapeutics secures **$60.3 million** in financing to eliminate outstanding debt and increase cash reserves from **$27.6 million** to **$49.7 million**, extending runway into late 2027. The company’s obesity treatment candidate, **RT-114**, progresses through **Phase 1 trials** following a **$1.085 billion** deal. Rani explores an oral pill alternative to injectable obesity therapies.

Mar 2026Stock TitanNews article